NCT06930755View on ClinicalTrials.gov

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

September 26, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

NMS-03305293

Route of administration: Oral

DRUG

Topotecan

Route of administration: Intravenous

Trial Locations (1)

37203

RECRUITING

Tennessee Oncology, Nashville

Sponsors
All Listed Sponsors
lead

Nerviano Medical Sciences

INDUSTRY

NCT06930755 - Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer | Biotech Hunter | Biotech Hunter